The Requirement for Cyclin D Function in Tumor Maintenance
Open accessAbstract
D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains that allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals' health. Ablation of cyclin D3 in mice bearing Notch1-driven T cell acute lymphoblastic leukemias (T-ALL) triggered tumor cell apoptosis. Such selective killing of leukemic cells can also be achieved by inhibiting cyclin D associated kinase activity in mouse and human T-ALL models. Inhibition of cyclin D-kinase activity represents a highly-selective anticancer strategy that specifically targets cancer cells without significantly affecting normal tissues.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Depending on cell type and transforming event, some Rb-positive cells undergo quiescence and others senescence after CDK4/6 inhibitor treatment.
“Depending on the cell type and the transforming event, some Rb-positive cells undergo quiescence and others undergo senescence when treated with CDK4/6 inhibitors (Baughn et al., 2006; Choi et al., 2012; Kovatcheva et al., 2015; Michaud et al., 2010; Puyol et al., 2010).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Choi et al., 2012
In T-cell acute lymphoblastic leukemia, inhibition of CDK6 or genetic repression of cyclin D3 induces apoptosis.
“In T-cell acute lymphoblastic leukemia (T-ALL), inhibition of CDK6 or genetic repression of cyclin D3 induces apoptosis (Choi et al., 2012; Sawai et al., 2012).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Choi et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works
Self-citationCell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1× · see citing works
“CyclinCDK complexes phosphorylate cellular proteins, thereby driving cell cycle progression (Malumbres and Barbacid, 2009).”
BackgroundModel-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133 · see citing works
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706 · see citing works
Self-citationRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 1× · see citing works
“Hypophosphorylated (active) pRB protein was shown to enforce the senescent state by permanently silencing expression of E2F target genes, such as cyclin E1, cyclin A2 or Dhfr (Chicas et al., 2010; Narita et al., 2003; Dean et al., 2010).”
BackgroundInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,915 · see citing works
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · see citing works
Hayashi, S., & McMahon, A. P. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0597 · Cited by 1,347 · see citing works
Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,246 · see citing works
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1× · see citing works
“As soon as breast tumors were detected, we started treating mice with PD 0332991, a specific and potent inhibitor of cyclin D-CDK4 and D-CDK6 kinases (Fry et al., 2004).”
BackgroundSibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158 · see citing works
Living with or without cyclins and cyclin-dependent kinases
Sherr, C. J., & Roberts, J. M. (2004) · Genes & Development · doi:10.1101/gad.1256504 · Cited by 1,089 · see citing works
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021 · see citing works
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L. R., Lees, E. M., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 964 · see citing works
Minireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 961 · see citing works
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · see citing works
Senescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909 · see citing works
Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.
Fantl, V, Stamp, G., Andrews, A., Rosewell, I., & Dickson, C. (1995) · Genes & Development · doi:10.1101/gad.9.19.2364 · Cited by 691 · see citing works
O’Neil, J., Grim, J. A., Strack, P. R., Rao, S. S., Tibbitts, D., Winter, C. G., Hardwick, J. S., Welcker, M., Meijerink, J. P. P., Pieters, R., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070876 · Cited by 662 · see citing works
Self-citationActivity-dependent regulation of inhibitory synapse development by Npas4
Lin, Y., Bloodgood, B. L., Hauser, J. L., Lapan, A. D., Koon, A. C., Kim, T.-K., Hu, L. S., Malik, A. N., & Greenberg, M. E. (2008) · Nature · doi:10.1038/nature07319 · Cited by 639 · see citing works
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · see citing works
Self-citationAcute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry
Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wysocki, J. M., & Jacks, T. (2003) · Nature · doi:10.1038/nature01764 · Cited by 538 · see citing works
Cyclins and cdks in development and cancer: a perspective
Deshpande, A., Siciński, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 467 · see citing works
Bodrug, S., Warner, B. J., Bath, M. L., Lindeman, G. J., Harris, A. W., & Adams, J. M. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06488.x · Cited by 440 · see citing works
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · see citing works
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works
Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice.
Lovec, H., Grzeschiczek, A., Kowalski, M., & Möröy, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06655.x · Cited by 406 · see citing works
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393 · see citing works
Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R. A., Narita, M., Zhang, M., & Lowe, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.023 · Cited by 388 · see citing works
Requirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicińska, E., Aifantis, I., Cam, L. L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 338 · see citing works
Weinstat‐Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., & Steeg, P. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1257 · Cited by 335 · see citing works
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329 · see citing works
GeneMerge—post-genomic analysis, data mining, and hypothesis testing
Castillo-Davis, C. I., & Hartl, D. L. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg114 · Cited by 301 · see citing works
E2F1-3 Switch from Activators in Progenitor Cells to Repressors in Differentiating Cells
Chong, J.-L., Wenzel, P. L., Sáenz-Robles, M., Nair, V., Ferrey, A., Hagan, J., Gomez, Y. M., Sharma, N., Chen, H.-Z., Ouseph, M. M., et al. (2009) · Nature · doi:10.1038/nature08677 · Cited by 259 · see citing works
Genetics and biology of adult human male germ cell tumors.
Chaganti, R. S. K., & Houldsworth, J. (2000) · PubMed · Cited by 248 · see citing works
FoxM1, a critical regulator of oxidative stress during oncogenesis
Park, H. J., Carr, J. R., Wang, Z., Nogueira, V., Hay, N., Tyner, A. L., Lau, L. F., Costa, R. H., & Raychaudhuri, P. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.239 · Cited by 234 · see citing works
Robles, A. I., Rodríguez‐Puebla, M. L., Glick, A. B., Trempus, C. S., Hansen, L. A., Siciński, P., Tennant, R. W., Weinberg, R. A., Yuspa, S. H., & Conti, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.16.2469 · Cited by 217 · see citing works
Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells
Kalaszczynska, I., Geng, Y., Iino, T., Mizuno, S.-I., Choi, Y., Kondratiuk, I., Silver, D. P., Wolgemuth, D. J., Akashi, K., & Sicinski, P. (2009) · Cell · doi:10.1016/j.cell.2009.04.062 · Cited by 215 · see citing works
Self-citationDivision and apoptosis of E2f-deficient retinal progenitors
Chen, D., Pacal, M., Wenzel, P., Knoepfler, P. S., Leone, G., & Bremner, R. (2009) · Nature · doi:10.1038/nature08544 · Cited by 144 · see citing works
Hulit, J., Wang, C., Li, Z., Albanese, C., Rao, M., Vizio, D. D., Shah, S., Byers, S. W., Mahmood, R., Augenlicht, L. H., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7598-7611.2004 · Cited by 143 · see citing works
Proapoptotic Function of the Retinoblastoma Tumor Suppressor Protein
Ianari, A., Natale, T., Calo, E., Ferretti, E., Alesse, E., Screpanti, I., Haigis, K. M., Gulino, A., & Lees, J. A. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.026 · Cited by 135 · see citing works
A unique function for cyclin D3 in early B cell development
Cooper, A. B., Sawai, C. M., Sicińska, E., Powers, S. E., Siciński, P., Clark, M. R., & Aifantis, I. (2006) · Nature Immunology · doi:10.1038/ni1324 · Cited by 126 · see citing works
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116 · see citing works
Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss
Tsikitis, M., Zhang, Z., Edelmann, W., Zagzag, D., & Kalpana, G. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505300102 · Cited by 109 · see citing works
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 105 · see citing works
Chiang, M. Y., Xu, M. L., Histen, G., Shestova, O. E., Roy, M., Nam, Y., Blacklow, S. C., Sacks, D. B., Pear, W. S., & Aster, J. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02478-05 · Cited by 105 · see citing works
FoxM1c Counteracts Oxidative Stress-induced Senescence and Stimulates Bmi-1 Expression
Li, S. K. M., Smith, D. K., Leung, W. Y., Cheung, A. M. S., Lam, E. W. ‐., Dimri, G. P., & Yao, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709604200 · Cited by 97 · see citing works
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1
Li, X., Gounari, F., Protopopov, A. I., Khazaie, K., & von Boehmer, H. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081561 · Cited by 97 · see citing works
Self-citationBowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61 · see citing works
Sanda, T., Li, X., Gutiérrez, A., Ahn, Y., Neuberg, D. S., O’Neil, J., Strack, P. R., Winter, C. G., Winter, S. S., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235143 · Cited by 60 · see citing works
Self-citationCDK4 and CDK6 Delay Senescence by Kinase-Dependent and p16INK4a-Independent Mechanisms
Ruas, M., Gregory, F. J., Jones, R., Poolman, R. A., Starborg, M., Rowe, J., Brookes, S., & Peters, G. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02286-06 · Cited by 57 · see citing works
Cyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin α Knockout Mice
Burns, K. H., Agno, J. E., Siciński, P., & Matzuk, M. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0038 · Cited by 53 · see citing works
In Vivo Pharmacodynamic Imaging of Proteasome Inhibition
Kimbrel, E. A., Davis, T. N., Bradner, J. E., & Kung, A. L. (2009) · Molecular Imaging · doi:10.2310/7290.2009.00007 · Cited by 49 · see citing works
Self-citationSicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45 · see citing works
Zhang, Q., Sakamoto, K., Liu, C., Triplett, A. A., Lin, W.-C., Rui, H., & Wagner, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1783 · Cited by 35 · see citing works
Differential regulation of apoptotic genes by Rb in human versus mouse cells
Young, A. P., & Longmore, G. D. (2004) · Oncogene · doi:10.1038/sj.onc.1207330 · Cited by 26 · see citing works
Flagged first, then by citations
Research works printed but not linked: 52
- Anders L Ke N Hydbring P Choi YJ Widlund HR Chick JM Zhai H Vidal M Gygi SP Braun P Sicinski P 2011 A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells Cancer Cell 20 620 634 22094256 PMC3237683
- Bodrug SE Warner BJ Bath ML Lindeman GJ Harris AW Adams JM 1994 Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene EMBO J 13 2124 2130 8187765 PMC395065
- Bowe DB Kenney NJ Adereth Y Maroulakou IG 2002 Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E Oncogene 21 291 298 11803472
- Burns KH Agno JE Sicinski P Matzuk MM 2003 Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin alpha knockout mice Mol Endocrinol 17 2053 2069 12855747
- Chaganti RS Houldsworth J 2000 Genetics and biology of adult human male germ cell tumors Cancer Res 60 1475 1482 10749107
- Chen D Pacal M Wenzel P Knoepfler PS Leone G Bremner R 2009 Division and apoptosis of E2f-deficient retinal progenitors Nature 462 925 929 20016601 PMC2813224
- Chiang MY Xu ML Histen G Shestova O Roy M Nam Y Blacklow SC Sacks DB Pear WS Aster JC 2006 Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1 Mol Cell Biol 26 6261 6271 16880534 PMC1592797
- Chicas A Wang X Zhang C McCurrach M Zhao Z Mert O Dickins RA Narita M Zhang M Lowe SW Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence Cancer Cell 17 376 387 20385362 PMC2889489
- Chong JL Wenzel PL Saenz-Robles MT Nair V Ferrey A 2009 E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells Nature 462 930 934 20016602 PMC2806193
- Cooper B Sawai C Sicinska E Powers S Sicinski P Clark M Aifantis I 2006 A unique function for cyclin D3 in early B cell development Nature Immunology 7 489 497 16582912
- Dean JL Thangavel C McClendon AK Reed CA Knudsen ES 2010 Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure Oncogene 29 4018 4032 20473330
- Deshpande A Sicinski P Hinds PW 2005 Cyclins and cdks in development and cancer: a perspective Oncogene 24 2909 2915 15838524
- Fantl V Stamp G Andrews A Rosewell I Dickson C 1995 Mice lacking cyclin D1 are small and show defects in eye and mammary gland development Genes Dev 9 2364 2372 7557388
- Fry DW Harvey PJ Keller PR Elliott WL 2004 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol Cancer Ther 3 1427 1438 15542782
- Fu M Wang C Li Z Sakamaki T Pestell RG 2004 Cyclin D1: normal and abnormal functions Endocrinology 145 5439 5447 15331580
- Hayashi S McMahon AP 2002 Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse Dev Biol 244 305 318 11944939
- Hu MG Deshpande A Enos M Mao D 2009 A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis Cancer Res 69 810 818 19155308 PMC2636510
- Hulit J Wang C Li Z Albanese C 2004 Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice Mol Cell Biol 24 7598 7611 15314168 PMC507010
- Ianari A Natale T Calo E Ferretti E Alesse E Screpanti I Haigis K Gulino A Lees JA 2009 Proapoptotic function of the retinoblastoma tumor suppressor protein Cancer Cell 15 184 194 19249677 PMC2880703
- Kimbrel EA Davis TN Bradner JE Kung AL 2009 In vivo pharmacodynamic imaging of proteasome inhibition Mol Imaging 8 140 147 19723471
- Kuhn R Schwenk F Aguet M Rajewsky K 1995 Inducible gene targeting in mice Science 269 1427 1429 7660125
- Kuilman T Peeper DS 2009 Senescence-messaging secretome: SMS-ing cellular stress Nat Rev Cancer 9 81 94 19132009
- Landis MW Pawlyk BS Li T Sicinski P Hinds PW 2006 Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis Cancer Cell 9 13 22 16413468
- Li X Gounari F Protopopov A Khazaie K von Behmer H 2008 Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1 J Exp Med 205 2851 61 18981238 PMC2585834
- Li SK Smith DK Leung WY Cheung AM Lam EW Dimri GP Yao KM 2008 FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression J Biol Chem 283 16545 53 18408007 PMC2423239
- Lin Y Bloodgood BL Hauser JL Lapan AD 2008 Activity-dependent regulation of inhibitory synapse development by Npas4 Nature 455 1198 1204 18815592 PMC2637532
- Lovec H Grzeschiczek A Kowalski MB Moroy T 1994 Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice EMBO J 13 3487 3495 8062825 PMC395252
- Malumbres M Barbacid M 2009 Cell cycle, CDKs and cancer: a changing paradigm Nat Rev Cancer 9 153 166 19238148
- Muller WJ Sinn E Pattengale PK Wallace R Leder P 1988 Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene Cell 54 105 115 2898299
- Musgrove EA Caldon CE Barraclough J Stone A Sutherland RL 2011 Cyclin D as a therapeutic target in cancer Nat Rev Cancer 11 558 572 21734724
- Narita M Nunez S Heard E Narita M Lin AW Hearn GA Spector DL Hannon GJ Lowe SW 2003 Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence Cell 113 703 716 12809602
- O’Neil J Grim J Strack P Rao S 2007 FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors J Exp Med 204 1813 1824 17646409 PMC2118656
- Park HJ Carr JR Wang Z Nogueira V 2009 FoxM1, a critical regulator of oxidative stress during oncogenesis EMBO J 28 2908 2918 19696738 PMC2760115
- Puyol M Martin A Dubus P Mulero F Pizcueta P Khan G Guerra C Santamaria D Barbacid M 2010 A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 18 63 73 20609353
- Reddy HK Mettus RV Rane SG Grana X Litvin J Reddy EP 2005 Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis Cancer Res 65 10174 10178 16288002
- Robles AI Rodriguez-Puebla ML Glick AB Trempus C Hansen L 1998 Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo Genes Dev 12 2469 2474 9716400 PMC317082
- Ruas M Gregory F Jones R Poolman R Starborg M Rowe J Brookes S Peters G 2007 CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms Mol Cell Biol 27 4273 4282 17420273 PMC1900050
- Sage J Miller AL Perez-Mancera PA Wysocki JM Jacks T 2003 Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry Nature 424 223 228 12853964
- Sanda T Li X Gutierrez A Ahn Y 2010 Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia Blood 115 1735 1745 20007543 PMC2832805
- Sherr CJ Roberts JM 2004 Living with or without cyclins and cyclin-dependent kinases Genes Dev 18 2699 2711 15545627
- Sicinska E Aifantis I Le Cam L Swat W 2003 Requirement for cyclin D3 in lymphocyte development and T cell leukemias Cancer Cell 4 451 461 14706337
- Sicinska E Lee YM Gits J Shigematsu H 2006 Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes Mol Cell Biol 26 8052 8060 16954383 PMC1636755
- Sicinski P Donaher JL Parker SB Li T 1995 Cyclin D1 provides a link between development and oncogenesis in the retina and breast Cell 82 621 630 7664341
- Trimarchi JM Lees JA 2002 Sibling rivalry in the E2F family Nat Rev Mol Cell Biol 3 11 20 11823794
- Tsikitis M Zhang Z Edelman W Zagzag D Kalpana GV 2005 Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss Proc Natl Acad Sci USA 102 12129 12134 16099835 PMC1189334
- Wang TC Cardiff RD Zukerberg L Lees E Arnold A Schmidt EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice Nature 369 669 671 8208295
- Weng AP Ferrando AA Lee W Morris JP Silverman JB Sanchez-Irizarry C Blacklow SC Aster JC 2004 Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia Science 306 269 271 15472075
- Weinstat-Saslow D Merino MJ Marrow RE Lawrence JA 1995 Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions Nat Med 1 1257 1260 7489405
- Young AP Longmore GD 2004 Differential regulation of apoptotic genes by Rb in human versus mouse cells Oncogene 23 2587 2599 15048095
- Yu Q Geng Y Sicinski P 2001 Specific protection against breast cancers by cyclin D1 ablation Nature 411 1017 1021 11429595
- Yu Q Sicinska E Geng Y Ahnstrom M Zagozdzon A Kong Y Gardner H Kiyokawa H Harris LN Stal O Sicinski P 2006 Requirement for CDK4 kinase function in breast cancer Cancer Cell 9 23 32 16413469
- Zhang Q Sakamoto K Liu C Triplett AA Lin WC Rui H Wagner KU Cyclin D3 compensates for the Loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression Cancer Res 71 7513 7524 22037875 PMC3242818
Cited by
Sorted by citations
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Siciński, P. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,873 · see citing works
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767 · see citing works
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137 · see citing works
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · see citing works
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Siciński, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 569 · see citing works
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 554 · see citing works
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528 · see citing works
Self-citationOvercoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470 · see citing works
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 494 · see citing works
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Siciński, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 480 · see citing works
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Siciński, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 462 · see citing works
Self-citationCDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · see citing works
Self-citationRB1 : a prototype tumor suppressor and an enigmaPreprint
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 437 · see citing works
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378 · see citing works
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez‐Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 395 · see citing works
Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels
Sobecki, M., Mrouj, K., Colinge, J., Gerbe, F., Jay, P., Krasińska, L., Dulić, V., & Fisher, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0707 · Cited by 378 · see citing works
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A. A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 379 · see citing works
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D. E., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 369 · see citing works
Self-citationThe metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347 · see citing works
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Pernas, S., & Tolaney, S. M. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833519 · Cited by 353 · see citing works
CDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316 · see citing works
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313 · see citing works
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285 · see citing works
Signaling through cyclin D-dependent kinases
Choi, Y., & Anders, L. (2013) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 279 · see citing works
Self-citationThe double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278 · see citing works
Circadian molecular clocks and cancer
Kelleher, F. C., Rao, A. D., & Maguire, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.040 · Cited by 276 · see citing works
Cancer and the Circadian Clock
Shafi, A. A., & Knudsen, K. E. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0566 · Cited by 257 · see citing works
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M. S., Dempsey, J. A., Zeng, Y. A., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236 · see citing works
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression
Lee, Y., Dominy, J. E., Choi, Y. J., Jurczak, M., Tolliday, N., Camporez, J. P., Chim, H., Lim, J.-H., Ruan, H.-B., Yang, X., et al. (2014) · Nature · doi:10.1038/nature13267 · Cited by 234 · see citing works
Self-citationTargeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 218 · see citing works
Cyclins and Cell Cycle Control in Cancer and Disease
Casimiro, M., Crosariol, M., Loro, E., Li, Z., & Pestell, R. G. (2012) · Genes & Cancer · doi:10.1177/1947601913479022 · Cited by 219 · see citing works
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204 · see citing works
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196 · see citing works
Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
Casimiro, M. C., Velasco-Velázquez, M. A., Aguirre-Alvarado, C., & Pestell, R. G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.867017 · Cited by 181 · see citing works
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168 · see citing works
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 168 · see citing works
Targeting CDK6 in cancer: State of the art and new insights
Tadesse, S., Yu, M., Kumarasiri, M., Le, B. T., & Wang, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1084445 · Cited by 166 · see citing works
Brett, J. O., Arjona, M., Ikeda, M., Quarta, M., de Morrée, A., Egner, I. M., Perandini, L. A., Ishak, H. D., Goshayeshi, A., Benjamin, D. I., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0190-0 · Cited by 162 · see citing works
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Xiong, Y., Zhong, Y., Yim, H., Yang, X., Park, K.-S., Xie, L., Poulikakos, P. I., Han, X., Xiong, Y., Chen, X., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09255 · Cited by 154 · see citing works
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148 · see citing works
Watt, A. C. S., & Goel, S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01510-6 · Cited by 151 · see citing works
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Henssen, A. G., Thor, T., Odersky, A., Heukamp, L. C., Hindy, N. E., Beckers, A., Speleman, F., Althoff, K., Schäfers, S., Schramm, A. R., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1534 · Cited by 146 · see citing works
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Dietrich, C. A., Trub, A. G., Ahn, A., Taylor, M., Ambani, K., Chan, K. T., Lu, K., Mahendra, C. A., Blyth, C., Coulson, R. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0954 · Cited by 141 · see citing works
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 138 · see citing works
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 134 · see citing works
Lee, Y., Lahens, N., Zhang, S. L., Bedont, J., Field, J., & Sehgal, A. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000228 · Cited by 104 · see citing works
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 126 · see citing works
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression
Bellail, A. C., Olson, J. J., & Hao, C. (2014) · Nature Communications · doi:10.1038/ncomms5234 · Cited by 124 · see citing works
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. A., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 122 · see citing works
Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.24 · Cited by 121 · see citing works
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119 · see citing works
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119 · see citing works
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114 · see citing works
Self-citationCiruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 114 · see citing works
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes
Daugaard, M., Nitsch, R., Razaghi, B., Mcdonald, L., Jarrar, A., Torrino, S., Castillo-Lluva, S., Rotblat, B., Li, L., Malliri, A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3180 · Cited by 106 · see citing works
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 112 · see citing works
Self-citationTargeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 110 · see citing works
Watt, A. C., Cejas, P., DeCristo, M. J., Metzger-Filho, O., Lam, E., Qiu, X., BrinJones, H., Kesten, N., Coulson, R., Font-Tello, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00135-y · Cited by 94 · see citing works
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 108 · see citing works
Ultrasound-Mediated Gene and Drug Delivery Using a Microbubble-Liposome Particle System
Yoon, Y. I., Kwon, Y., Cho, H.-S., Heo, S., Park, K. S., Park, S. G., Lee, S.-H., Hwang, S. I., Kim, Y. I., Jae, H. J., et al. (2014) · Theranostics · doi:10.7150/thno.9945 · Cited by 107 · see citing works
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Zhang, J., Xu, K. L., Liu, P., Geng, Y., Wang, B., Gan, W., Guo, J., Wu, F., Chin, Y. R., Berrios, C. J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.023 · Cited by 106 · see citing works
Qie, S., Yoshida, A., Parnham, S. R., Oleinik, N. V., Beeson, G. C., Beeson, C. C., Öğretmen, B., Bass, A. J., Wong, K., Rustgi, A. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09179-w · Cited by 101 · see citing works
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102 · see citing works
Sangar, M. L. C., Genovesi, L. A., Nakamoto, M. W., Davis, M. J., Knobluagh, S. E., Ji, P., Millar, A., Wainwright, B. J., & Olson, J. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2943 · Cited by 102 · see citing works
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 102 · see citing works
Miettinen, T. P., Peltier, J., Härtlová, A., Gierliński, M., Jansen, V. M., Trost, M., & Björklund, M. (2018) · The EMBO Journal · doi:10.15252/embj.201798359 · Cited by 99 · see citing works
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor–Resistant Cutaneous Melanomas
Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.418 · Cited by 99 · see citing works
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Hydbring, P., Wang, Y., Fassl, A., Li, X., Matía, V., Otto, T., Choi, Y. J., Sweeney, K. E., Suski, J. M., Yin, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.004 · Cited by 97 · see citing works
Self-citationLi, X., Liu, L. L., Yao, J. L., Wang, K., & Ai, H. (2019) · Stem Cells International · doi:10.1155/2019/8108576 · Cited by 93 · see citing works
Self-citationFassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 91 · see citing works
New cast for a new era: preclinical cancer drug development revisited
Herter-Sprie, G. S., Kung, A. L., & Wong, K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68340 · Cited by 91 · see citing works
Self-citationWitkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021) · Genes & Cancer · doi:10.18632/genesandcancer.211 · Cited by 93 · see citing works
Wong, R. W. J., Ngoc, P. C. T., Leong, W. Z., Yam, A. W. Y., Zhang, T., Asamitsu, K., Iida, S., Okamoto, T., Ueda, R., Gray, N. S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-792184 · Cited by 89 · see citing works
Self-citationDivision of labour between Myc and G1 cyclins in cell cycle commitment and pace control
Dong, P., Maddali, M. V., Srimani, J. K., Thélot, F. A., Nevins, J. R., Mathey-Prévôt, B., & You, L. (2014) · Nature Communications · doi:10.1038/ncomms5750 · Cited by 84 · see citing works
Wang, Q., Guldner, I. H., Golomb, S. M., Sun, L., Harris, J. A., Lü, X., & Zhang, S. (2019) · Nature Communications · doi:10.1038/s41467-019-11729-1 · Cited by 87 · see citing works
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
Scott, S. C., Lee, S. S., & Abraham, J. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.01.006 · Cited by 87 · see citing works
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 78 · see citing works
Fu, H., Gao, H., Qi, X., Zhao, L., Wu, D., Bai, Y., Li, H., Liu, X., Hu, J. X., & Shao, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0290-3 · Cited by 80 · see citing works
Glaviano, A., Wander, S. A., Baird, R. D., Yap, K. C.-Y., Lam, H. Y., Toi, M., Carbone, D., Geoerger, B., Serra, V., Jones, R. H., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101103 · Cited by 85 · see citing works
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 79 · see citing works
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer, C. L., Boras, B. W., Pascual, B., Li, N., Li, D., Garza, S. J., Huser, N. H., Yuan, J. T., Cianfrogna, J. A., Sung, T., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.006 · Cited by 79 · see citing works
JING, X., Cheng, W., Wang, S., Li, P., & Li, H. (2015) · Oncology Reports · doi:10.3892/or.2015.4384 · Cited by 76 · see citing works
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 76 · see citing works
Ravindranathan, P., Pasham, D., Balaji, U., Cardenas, J., Gu, J., Toden, S., & Goel, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32267-8 · Cited by 75 · see citing works
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 74 · see citing works
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 73 · see citing works
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 71 · see citing works
Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest
Foy, R., Crozier, L., Pareri, A. U., Valverde, J. M., Park, B. H., Ly, T., & Saurin, A. T. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.020 · Cited by 75 · see citing works
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 71 · see citing works
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 70 · see citing works
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69 · see citing works
miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4
Feng, T., Xu, D., Tu, C., Li, W., Ning, Y., Ding, J., Wang, S., Yuan, L., Xu, N., Qian, K., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3275-8 · Cited by 68 · see citing works
Bisteau, X., Paternot, S., Bianca, C., Ecker, K., Coulonval, K., Groote, P. D., Declercq, W., Hengst, L., & Roger, P. P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003546 · Cited by 66 · see citing works
Guo, B., Li, L., Guo, J., Liu, A., Wu, J., Wang, H., Shi, J., Pang, D., & Cao, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17973 · Cited by 66 · see citing works
Cyclin D/CDK4/6 activity controls G1 length in mammalian cells
Dong, P., Zhang, C., Parker, B., You, L., & Mathey-Prévôt, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0185637 · Cited by 64 · see citing works
MicroRNA-188 suppresses G 1 /S transition by targeting multiple cyclin/CDK complexes
Wu, J., Lv, Q., He, J., Zhang, H., Mei, X., Cui, K., Huang, N., Xie, W., Xu, N., & Zhang, Y. (2014) · Cell Communication and Signaling · doi:10.1186/s12964-014-0066-6 · Cited by 64 · see citing works
Polycarpou, E., Meira, L. B., Carrington, S. J., Tyrrell, E., Modjtahedi, H., & Carew, M. A. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200742 · Cited by 61 · see citing works
- Authors
- Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Boston Children's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 22
- Issue
- 4
- Pages
- 438-451
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3487466
- OpenAlex
- W2126821691
- Cited by
- 342
- References
- 56
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 23 · 2023: 27 · 2022: 30 · 2021: 20 · 2020: 31 · 2019: 29 · 2018: 32 · 2017: 36 · 2016: 24 · 2015: 19 · 2014: 27 · 2013: 17 · 2012: 3
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 380 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P01 CA080111, P01 CA109901, R01 CA083688)
- National Cancer Institute (1K99CA157951)
- Novartis
- Children’s Leukemia Research Association
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- cyclin D1, cyclin D3, tumor maintenance, cell cycle, tumor cell senescence, apoptosis, breast cancer, targeted cancer therapy
- MeSH terms
- Animals, Female, Humans, Mammary Neoplasms, Experimental, Neoplasms, Apoptosis, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cyclin-Dependent Kinase 4, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
